The Business Advisory Board is composed of leaders in the life-sciences and finance world with experience in the pharmaceutical, biotechnology, medical device, investment banking, venture capital and financial management industries. The BAB members assess grant and investment opportunities and provide advice and direction to support the commercialization of new therapies. The BAB members also work with the SAB and the Board in setting strategic direction to guide the organization and our programs.
- Stephen D. Collins, M.D., Ph.D.: Co-Chair, Business Advisory Board
President & CEO, NeuroTherapeutics Pharma, Inc.
- Garry E. Menzel, Ph.D.: Co-Chair, Business Advisory Board
Executive Vice President Corporate Development and Finance, Regulus Therapeutics
- Karen L. Bergman
Founder and Principal, BCC Partners
- Thomas A. Bologna
President & Chief Executive Officer, Orchid Cellmark, Inc.
- Frank Fischer
President & CEO, NeuroPace, Inc.
- Jeffrey D. Glidden
Executive Vice President & Chief Financial Officer, Parametric Technology Corporation
- Nina Graves, PharmD.
Retired (Former) Epilepsy Program Director, Medtronic Inc.
- Warren Lammert
Founder, Managing Partner Granite Point Capital
- Lisa Lindahl
Chief Executive Instigator at EZL Enterprises and Co-Founder and Partner at Bellisse
- Heath Lukatch, Ph.D.
Partner, Novo Ventures
- Daniel J. O'Connell
Director, NeuroVentures Capital LLC
- Sherrie Perkins
Senior Director New Business Development, Cyberonics, Inc.
- David A. Sadock
President & CEO, Ethos Health Communications
- Aaron Sandoski
Managing Director, Norwich Ventures
- Nancy Santilli, B.S.N., M.S.N.
VP Commercial Strategy and Portfolio Planning, Endo Pharmaceuticals, Inc.
- Ned Scheetz
Managing Director, Aphelion Capital, LLC
- Randy Siegel
President, Local Digital Strategy, Advance Publications, Inc.
- Lauren Silverman, Ph.D.
Managing Director, Novartis Option Fund
- Matthew Simonian
Senior Director, Epilepsy Marketing, Cyberonics, Inc.
- Reese S. Terry, Jr.
Founder, Cyberonics, Inc.
- Elizabeth S. Weiswasser
Litigation Partner, Weil, Gotshal & Manges LLP
- Gregory T. Went, Ph.D.
Chief Executive Officer and Chairman, Adamas Pharmaceuticals, Inc.